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Abstract
Amenamevir (formerly ASP2151) is a helicase-primase inhibitor being developed for the treatment of herpesvirus infec-
tion. Amenamevir is both a substrate and inducer of cytochrome P450 (CYP) 3A4. Three studies were done in healthy
volunteers to investigate potential CYP3A pharmacokinetic interactions with the following drugs: (1) Midazolam (probe
substrate for CYP3A):After 10 days’ pretreatment with amenamevir 400 mg daily, geometric mean maximum concentra-
tion of drug in blood plasma (Cmax) and area under the plasma drug concentration-time curve from time zero to infinity
(AUC0-) of midazolam 7.5 mg were about 68% and 51%, respectively, of those after midazolam alone. (2) Cyclosporine
(substrate and inhibitor of CYP3A): After 5 days’ pretreatment with cyclosporine 100 mg twice daily, geometric mean
Cmax of amenamevir after 400-mg and 1200-mg single doses was, respectively, about 66% and 69%, and AUC0- about
82% and 79%, of those after amenamevir alone. (3) Ritonavir (inhibitor of CYP3A): When given with single doses of
ritonavir 600 mg, geometric mean Cmax of amenamevir after 400-mg and 1200-mg single doses was, respectively, about
1.4 and 1.6 times higher, and geometric mean AUC0- about 2.6 and 3.3 times higher, than after amenamevir alone.
Amenamevir has the potential to be involved in CYP3A-mediated pharmacokinetic interactions in clinical practice.
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Amenamevir, an oxadiazolephenyl derivative (see
Figure 1),1 is a nonnucleoside helicase-primase in-
hibitor being developed for the treatment of herpes
simplex virus types 1 and 2 (HSV-1 and HSV-2),
and varicella zoster virus (VZV) infection. The viral
helicase-primase complex is essential for viral DNA
replication.
Nucleoside analogues such as acyclovir and vala-
cyclovir are currently first-line treatment for HSV and
VZV.2 Drug-resistant HSV infection is unusual in
immunocompetent patients but is more common in
immunocompromised individuals, in whom it is more
likely to be clinically important.3 Amenamevir has
good activity against acyclovir-resistant VZV strains in
vitro1 and therefore might be effective in the treatment
of infection with virus resistant to first-line antiviral
drugs.
The pharmacokinetics and metabolic profile of
amenamevir have previously been studied (unpub-
lished data held by Maruho). In healthy volunteers,
amenamevir was rapidly absorbed after single, oral ad-
ministration, with time of peak concentration of 1.33 to
2.5 hours. Plasma protein binding of 14C-amenamevir
in humans was about 75%. Elimination half-life was
about 7 to 8 hours andwas independent of dose over the
range of 5 to 2400 mg. After a single oral dose of 200
mg 14C-amenamevir, 74.6% of the 14C radioactivity was
recovered in feces; the remainder was recovered in urine.
1Hammersmith Medicines Research, London, England
2Maruho Co Ltd, Kyoto, Japan
3Analytical Services International, St George’s University of London,
London, England
This is an open access article under the terms of the Creative Com-
mons Attribution-NonCommercial License, which permits use, distri-
bution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
Submitted for publication 21 August 2017; accepted 18 May 2018.
Corresponding Author:
Steve Warrington, MD, FRCP, Hammersmith Medicines Research,
Cumberland Avenue, London, NW10 7EW, England.
(e-mail: swarrington@hmrlondon.com)
2 Clinical Pharmacology in Drug Development 2018, 00(0)
Figure 1. Molecular structure of amenamevir.1
Studies of 14C-amenamevir using cells expressing the
humanmultidrug resistance transporter P-glycoprotein
(P-gp) and the human multidrug resistance-associated
protein-2 showed that amenamevir is a substrate of the
human multidrug resistance P-gp transporter but not
of the humanmultidrug resistance-associated protein-2
transporter. There was no uptake of 14C-amenamevir
into organic anion transporting polypeptide (OAT)
P1B1-, OATP1B3-, OAT1- and OAT3-, and organic
cation uptake transporter-2–expressing cells, which
suggests that amenamevir is not a substrate of those
transporters. In vitro studies using human liver mi-
crosomes show that cytochrome P450 (CYP) 3A4/5
are the main isozymes involved in the metabolism
of amenamevir. A major metabolite of amenamevir
in human plasma was the monohydroxy metabolite
AS1955888-00. The metabolite/parent compound ratio
was 0.1. The antiherpetic potency of amenamevir, as
judged by half maximal effective concentration values,
was much greater than that of AS1955888-00: up to
12-fold greater for HSV-1, up to 8-fold for HSV-2, and
up to 4-fold for VZV. Amenamevir 1 to 100μMshowed
the potential to induce CYP3A4 in human hepatocytes
but had very weak or no inhibitory activity against
CYP3A4/5 (half maximal inhibitory concentration
>100 μM).
Thus, amenamevir is both a substrate and inducer
of CYP3A. CYP3A comprises over 30% of hepatic en-
zymes and is involved in the metabolism of more than
50% of medicines that undergo metabolic elimination.4
CYP3A interactions involving amenamevir could
therefore be clinically relevant.
In this paper, we describe 3 studies that investigated,
in healthy volunteers, potential pharmacokinetic inter-
actions mediated by CYP3A. The rationale for our
choice of drugs was as follows:
(1) Midazolam. In this study, we tested the ability of
amenamevir to induce CYP3A, using midazolam
(a sedative) as a “probe” substrate.5 We used a sin-
gle oral dose of midazolam 7.5 mg, which is within
the recommended therapeutic range and is gener-
ally well tolerated, albeit somewhat sedative.6
(2) Cyclosporine. In this study, we tested the suscep-
tibility of amenamevir to inhibition of CYP3A
by cyclosporine, an immunosuppressant that is
both a substrate and an inhibitor of CYP3A.7 Im-
munocompromised status increases the frequency
of reactivation and the severity of symptoms of
herpesvirus infection.3 Thus, many patients tak-
ing immunomodulator therapy and patients in-
fected with HIV (see ritonavir section below) are
likely to be treated with amenamevir. We preferred
cyclosporine to tacrolimus because cyclosporine
is a stronger CYP3A inhibitor. In clinical prac-
tice, the usual oral dose of cyclosporine is 2.5 to
15 mg/kg/day,8 equivalent to about 175 to 1050 mg
daily in a 70-kg subject. We chose to give cy-
closporine 100 mg twice daily, which we considered
low enough to be safe but high enough to allow de-
tection of drug interactions mediated by CYP3A.
(3) Ritonavir. In this study, we tested the suscepti-
bility of amenamevir to CYP3A inhibition by
ritonavir, an antiretroviral drug that is a powerful
inhibitor of CYP3A.9 Ritonavir is often used to
“boost” the circulating concentrations of other
protease inhibitors, most of which are substrates
for CYP3A.10 We chose a single dose of 600 mg
because repeated doses of that size are poorly
tolerated,11 and Kempf et al12 showed that a single
concomitant dose of 600-mg ritonavir increased
the plasma concentrations of saquinavir >50-fold.
Subjects and Methods
All Studies
All 3 studies were done at Hammersmith Medicines
Research (HMR), London, after approval by the
Medicines and Healthcare Products Regulatory
Agency (MHRA) and London-Brent Research Ethics
Committee. The studies were conducted in accordance
with the ethical principles outlined in the Declaration
of Helsinki. All subjects gave written, informed consent
before the start of the study.
Subjects
The subjects comprised healthymen aged 18 to 45 years
who had a body mass index of 18.0 to 30.9 kg/m2 and
were capable of giving informed consent. Subjects were
deemed healthy on the basis of clinical history, med-
ical examination, electrocardiogram, vital signs, and
clinical laboratory tests of routine hematology, bio-
chemistry, and urinalysis. Subjects were excluded if,
during the 28 days before dosing, they had used any pre-
scription or nonprescriptionmedicine or herbal remedy
known to interfere with CYP3A activity.
Midazolam Study
This was a phase 1, open-label, single-center, drug-drug
interaction study in 18 healthy men aged 20 to 43 years
(see Table 1).
Each subject received 4 single oral doses of 7.5-mg
midazolam on days 1, 12, 19, and 26, and 10 daily
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Table 1. Summary of Demographic Details of Subjects in All 3 Studies
Ritonavir Study (N = 48)
Midazolam
Study
(N = 18)
Cyclosporine
Study
(N = 26)b
Group 1
(N = 24)
Group 2
(N = 24)
Age (y) Mean (SD) 30.7 (7.53) 32.7 (7.2) 28.2 (6.4) 27.0 (4.9)
Range 20-43 20-45 19-42 18-36
Race
Asian n (%) 2 (11.1) 0 (0) 1 (4.2) 3 (12.5)
Black 4 (22.2) 0 (0) 4 (16.7) 5 (20.8)
White 11 (61.1) 26 (100) 17 (70.8) 15 (62.5)
Other 1 (5.6) 0 (0) 2 (8.3) 1 (4.2)
Height (cm) Mean (SD) 176.7 (4.8) 182.4 (6.5) 179.8
(6.8)
178.2 (7.2)
Range 166-184 173-202 165-196 167-190
Weight (kg) Mean (SD) 75.4 (9.8) 81.4 (8.2) 79.1 (7.8) 75.5 (11.3)
Range 56.7-91.5 67.9-96.1 62.0-92.1 58.2-104.9
BMI Mean (SD) 24.1 (2.7) 24.5 (2.2) 24.5 (2.5) 23.7 (2.9)
kg/m2 Range 18.9-28.5 20.6-29.0 19.9-30.1 19.2-29.1
Smoker n (%) 0 2 (7.7) 6 (25.0) 3 (12.5)
Cigarettes1 (daily) Mean (SD) 2 (1.4) 3.3 (1.5) 3.7 (2.3)
Range 1-3 2-5 2-5
Consumes
alcohol
n (%) 11 (61.1) 2 (1.4) 20 (83.3) 12 (50)
Units/weeka Mean (SD) 4.5 (3.1) 5.8 (4.8) 7.4 (4.0) 6.3 (5.4)
Range 2-11 1-20 2-16 1-16
BMI, body mass index; SD, standard deviation.
aIncludes only those subjects who smoke/drink alcohol.
bIncludes 2 replacement subjects.
doses of 400-mg amenamevir on days 3 through 12 (see
Figure 2A). On day 12, the doses of midazolam and
amenamevir were administered at the same time. We
chose a dose level of 400-mg instead of 1200-mg ame-
namevir because 1200-mg amenamevir is being devel-
oped only as a single dose, and repeated doses are
needed to assess enzyme induction. Blood samples for
midazolam and 1-hydroxymidazolam assay were taken
before and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and
24 hours after each dose of midazolam.
To assess the return of CYP3A activity to base-
line, the effect of amenamevir on midazolam and
1-hydroxymidazolam was assessed on days 19 and 26
using the analysis of variance model described above.
The 95% confidence interval (CI) for the difference in
means (day 19 vs day 1 and day 26 vs day 1) were used to
determine how long it took for the CYP3A levels to
return to normal.
Cyclosporine Study
This was a randomized, phase 1, open-label,
single-center, balanced 2-way crossover, drug-drug
interaction study in 24 healthy men aged 20 to 45 years
(see Table 1).
Each subject underwent 2 treatment sessions in
which they received single oral doses of amenamevir
(400 mg in one session, 1200 mg in the other) on days
1 and 7, and cyclosporine 100 mg twice daily on days
3 through 9, and once in the morning of day 10 (see
Figure 2B). On day 7, the doses of amenamevir and cy-
closporine were administered at the same time. Twelve
subjects were randomized to receive the 400-mg dose
of amenamevir in treatment session 1 and the 1200-mg
dose in treatment session 2, and 12 were randomized
to receive the 1200-mg dose in treatment session 1 fol-
lowed by the 400-mg dose in treatment session 2. There
was a washout of at least 2 weeks between treatment
sessions.
Blood samples for assay of amenamevir and its
metabolite AS1955888-00 were taken before and at 0.5,
1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours on days 1 and
7 after each dose of amenamevir, and at 72 hours after
each dose of amenamevir on day 7. Blood samples for
assay of cyclosporine were taken before, and at 0.5, 1,
2, 3, 4, 6, 8, 10, and 12 hours after, morning doses of
cyclosporine on days 6 and 7 only.
Ritonavir Study
A randomized, phase 1, open-label, balanced 2-way
crossover, drug-drug interaction study in 48 healthy
men aged 18 to 42 years (see Table 1).
The subjects were randomized to receive single doses
of amenamevir 400 mg (n = 24) or 1200 mg (n =
24) in 2 treatment sessions. Each subject was further
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Figure 2. (A) Midazolam study schematic; (B) cyclosporine study schematic showing 1 treatment session (each subject underwent 2
such sessions, separated by a minimum 2-week washout); (C) ritonavir study schematic.
randomized to receive amenamevir alone in the first ses-
sion, followed by amenamevir with a single dose of ri-
tonavir 600 mg (administered at the same time) in the
second session, or vice versa (see Figure 2C). Blood
samples for assay of amenamevir and its metabolite
AS1955888-00 were taken before and at 0.5, 1, 2, 3, 4, 6,
8, 10, 12, 24, 36, 48, and 72 hours after each dose. There
was a washout of at least 2 weeks between treatment
sessions.
Blood samples for ritonavir assay were taken before
and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours after each
dose.
Safety and Tolerability Assessments
Safety and tolerability assessments included adverse
events, vital signs, 12-lead electrocardiogram, physical
examination, and clinical laboratory tests.
Assay of Amenamevir and Its Metabolite
AS1955888-00
Blood samples for assay of amenamevir and
AS1955888-00 (2 mL) were collected in sodium
heparin tubes. Plasma was separated by centrifugation
at 1500 G for 10 min at 4°C, then stored at –20°C or
below until analysis by Shin Nippon Biomedical Labo-
ratories Ltd, using a validated liquid chromatography
tandem mass spectrometry (LC-MS/MS) method as
follows.
Internal Standard. YM-385482 and AS2357699-00
(both 100 μg/mL in acetonitrile) were diluted with 50%
acetonitrile solution to yield a final concentration of
400 ng/mL of each analyte.
Calibrators. Deuterated amenamevir (2.5 mg/mL
in acetonitrile) and deuterated AS1955888-00
(1.25 mg/mL in 50% acetonitrile) were diluted with
50% acetonitrile to yield final concentrations of 25 to
1 000 000 ng/mL amenamevir and 10 to 400 000 ng/mL
AS1955888-00.
Analytical Method. Samples were extracted using the
organic solvent t–butyl methyl ether (MTBE).
20 μL of 50% acetonitrile solution and 50 μL of
internal standard were added to 100-μL plasma sam-
ples and mixed; 100 μL of 5% ammonia solution and
2.5 mL of t-MTBE were then added and the sam-
ples centrifuged. The samples were placed in a dry
ice/acetone bath to freeze the aqueous layer. The or-
ganic layer was then removed and evaporated to dry-
ness under a stream of nitrogen at 40°C. The residue
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was reconstituted in 1 mL of acetonitrile/ultrapure wa-
ter/formic acid (98%) 50:50:0.1 v/v/v for analysis by LC-
MS/MS.
High-Performance Liquid Chromatography (HPLC) Condi-
tions.
Column Chromolith SpeedROD RP–18e (50 mm ×
4.6 mm i.d., Phenomenex Inc.)
Mobile phase Methanol/ultrapure water/formic acid,
60:40:0.1, v/v/v
Elution Isocratic
Flow rate 0.5 mL/min
Injection volume 5 μL
Mass Spectrometry Settings.
MS type Multiple Reaction Monitoring (MRM)
Ionisation type ESI (TurboIonSpray)
Ionisation polarity Positive
Compound Q1 (m/z) Q3 (m/z)
Amenamevir 483 322
AS1955888–00 499 338
YM-385482 (IS substance-1) 489 328
AS2357699-00 (IS substance-2) 504 338
Variability.
Compound
Concentration
(ng/mL)
Mean
(ng/mL)
Precision
(%CV)
Accuracy
(Relative
Error) (%)
Amenamevir 5 5.28 4.5 105.6
10 10.12 3.9 101.2
500 510.4 2.6 102.1
4000 4017 2.1 100.4
AS1955888-
00
2 2.07 5.2 103.7
4 4.04 6.2 101.1
200 202.8 4.0 101.4
1600 1613 3.8 100.8
CV, coefficient of variation.
The lower limit of reliable quantification was 5 ng/
mL for amenamevir and 2 ng/mL for AS1955888-00.
Assay of Other Drugs. Blood samples for assay of mi-
dazolam, its metabolite 1-hydroxymidazolam (3 mL),
and ritonavir (2 mL) were collected in lithium heparin
tubes. Blood samples for assay of cyclosporine (2 mL)
were collected in ethylenediaminetetraacetic acid tubes.
Plasma was separated using the same method as
for amenamevir and AS1955888-00 and stored at –
20°C until analysis by Analytical Services International
using validated LC-MS/MS as follows.
Midazolam
Internal Standard. MidazolamD4maleate and alpha-
hydroxymidazolam-D4 (both 100 μg/mL in methanol)
were diluted with 0.1% formic acid to a final concentra-
tion of 50 ng/mL of each analyte.
Calibrators. The calibrators were 0.1 to 100.0 ng/mL
midazolam and α-hydroxymidazolam in 0.1% formic
acid.
Analytical Method. Samples were extracted using the
organic solvent MTBE.
The following were added to a polypropylene tube:
250 μL plasma sample (or 250 μL blank plasma, for
calibration samples)
250 μL 0.1% formic acid (or 250 μL calibrator, for cal-
ibration samples)
100 μL internal standard
500 μL 2 M Tris (containing Orange G)
2 mL MTBE
The organic phase supernatantwas separated by cen-
trifugation, then evaporated to dryness in a vacuum.
The residue was reconstituted with 250 μL of 10%
methanol and briefly vortexed before analysis by LC-
MS/MS.
HPLC Conditions.
Column Chromolith RP-18e column (100 mm × 3 mm)
Mobile phase Methanol
Formic acid 0.1% solution in deionized water
Elution Isocratic
Flow rate 0.30 mL/min
Injection
volume
5 μL
MS Settings.
MS type Sciex API4000
Ionization type TurboIonSpray
Ionisation polarity Positive
Midazolam mass ratio 326.1/291.0 amu
Midazolam standard mass ratio 330.2/295.0 amu
Hydroxymidazolam mass ratio 342.1/323.9 amu
Hydroxymidazolam standard mass ratio 346.1/328.0 amu
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Variability.
Concentration Mean Precision
Accuracy
(Relative
Error)
Midazolam (ng/mL) (ng/mL) (%CV) (%)
QC1 0.300 0.29 9.50 97.77
QC2 30.00 29.78 4.86 99.26
QC3 80.00 75.78 5.06 94.72
α-
Hydroxymidazolam
Concentration
(ng/mL)
Mean
(ng/mL)
Precision
(%CV)
Accuracy
(Relative
Error)
(%)
QC1 0.300 0.29 9.03 97.04
QC2 30.00 31.57 3.97 105.25
QC3 80.00 80.29 4.63 100.37
CV, coefficient of variation.
Cyclosporine
Internal Standard. Cyclosporine-D12 (0.504 mg/mL
cyclosporine-D12 in methanol) was diluted with 25%
ethanol:25% ethanediol:50% deionized water to a final
concentration of 250 ng/mL.
Calibrators. Cyclosporine (987.97 μg/mL in
methanol) was diluted with whole blood to yield
final concentrations of 24.7 to 1976.0 ng/mL.
Analytical Method. Samples were prepared by protein
precipitation and liquid-liquid extraction.
The following were added to a polypropylene tube:
50 μL plasma sample, calibrator or quality control
50 μL internal standard
500 μL 5% zinc sulphate
500 μL acetone
After centrifugation the supernatant was added to
0.1 mL of 0.1-M sodium hydroxide and 2 mL of
MTBE, then mixed and centrifuged. The resulting sol-
vent layer was evaporated to dryness in a vacuum. The
residue was reconstituted in 250 μL of 80% methanol,
centrifuged, and the resulting supernatant analyzed by
LC-MS/MS.
HPLC Conditions.
Column Alltima C18 (150 mm × 2.1 mm, 5 μm)
Mobile phase Ammonium acetate 0.01-M solution in 85%
methanol
Elution Isocratic
Flow rate 0.40 mL/min
Injection
volume
5–30 μL
MS Settings.
MS type MRM
Ionisation type TurboIonSpray
Ionisation polarity Positive
Cyclosporine mass ratio 1220.0/1202.8 amu
Cyclosporine standard mass ratio 1232.1/1215.0 amu
Variability.
Concentration Mean Precision
Accuracy
(Relative
Error)
Cyclosporine (μg/L) (μg/L) (%CV) (%)
QC1 1482 1344.57 3.66 90.73
QC2 741 698.27 3.63 94.23
QC3 74.1 73.28 3.50 98.90
CV, coefficient of variation.
Ritonavir
Internal Standard. Ritonavir-d6 (0.05 mg/mL in
methanol) was diluted with methanol/deionized water
(50/50 v/v) to a final concentration of 10 μg/mL.
Calibrators. Ritonavir (100.2 μg/mL in methanol)
was diluted with plasma to yield final concentrations
of 0.5 to 25.0 μg/mL.
Analytical Method. Samples were extracted by protein
precipitation.
The following were added to a polypropylene tube:
50 μL plasma sample, calibrator or quality control
50 μL internal standard
1 mL acetonitrile
After centrifugation, the supernatant was mixed
with 5 mL of deionized water and analysed by LC-
MS/MS.
HPLC Conditions.
Column Alltima C18 (150 mm × 2.1 mm; 5 μm)
Mobile phase Deionized water supplemented with 2 mM of
ammonium acetate and 0.1% formic acid,
about 15%
Methanol, deionized water, 2 mM of
ammonium acetate and 0.1% formic acid,
about 85%
Elution Isocratic
Flow rate 0.40 mL/min
Injection
volume
5 μL
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MS Settings.
MS type MRM
Ionisation type TurboIonSpray
Ionisation polarity Positive
Ritonavir mass ratio 721.2/296.1 amu
Ritonavir standard mass ratio 727.1/302.0 amu
Variability.
Ritonavir
Concentration
(μg/L)
Mean
(μg/L)
Precision
(%CV)
Accuracy
(Relative
Error)(%)
QC1 1.5 1.53 8.26 101.96
QC2 7.5 7.32 5.02 97.55
QC3 20.0 21.07 4.09 105.34
CV, coefficient of variation.
The lower limit of reliable quantification was
0.1 ng/mL for midazolam and 1-hydroxymidazolam,
25 ng/mL for cyclosporine, and 500 ng/mL for ritonavir.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic parameters were calculated using
WinNonlin version 6.3. Lower limit of reliable quan-
tification values were taken as zero, unless they fell be-
tween 2 quantifiable concentrations, in which case they
were treated as missing. Interactions were tested us-
ing an equivalence analysis as follows: area under the
plasma drug concentration-time curve from time zero
to infinity (AUC0-) and maximum concentration of
drug in blood plasma (Cmax) of the substrate drug were
logarithmically transformed and subjected to analysis
of variance with treatment dose, group, sequence, ses-
sion, and dose by treatment interaction as fixed effects,
and subject as a random effect. The least square mean
of the treatment difference and its 90%CI were trans-
formed to the original scale, to obtain mean AUC0-
andCmax ratios. Absence of a clinically significant drug-
drug interaction was concluded if the 90%CI for both
AUC0- and Cmax ratios fell within the prespecified
interval of 80% to 125%.
Results
Midazolam Study
Plasma concentrations and AUC0- of midazolam
were significantly reduced when midazolam was ad-
ministered with the last of 10 daily doses of 400-mg
amenamevir, compared with midazolam given before
treatment with amenamevir (see Figure 3 and Table 2).
Elimination half-life of midazolam was also shortened
by amenamevir from 4.2 to 3.3 hours.
Exposure to midazolam 7 and 14 days after the
last dose of amenamevir was similar to that before
amenamevir dosing (see Table 2).
After midazolam with amenamevir, geometric mean
Cmax and AUC0- of midazolam were about 68%
and 51%, respectively, of that after midazolam alone
(see Table 2). Results failed to exclude a significant
drug-drug effect (the 90%CI of the log ratio midazolam
with amenamevir:midazolam did not fall within the
range 80%-125% for Cmax or AUC0-).
Plasma concentrations of 1-hydroxymidazolamwere
not influenced by coadministration of amenamevir (see
Figure 3 and Table S1): They remained about half those
of unchanged midazolam.
Somnolence was the most common adverse event
and was reported by every subject after 1 or more
of their 4 doses of midazolam. No subject reported
somnolence while receiving amenamevir alone.
Cyclosporine Study
Plasma concentrations (1-12 hours after dose) and
AUC0- of amenamevir were reduced after coadminis-
tration with cyclosporine compared with amenamevir
alone (see Figure 4 and Table 3).
After 400 mg of amenamevir with cyclosporine,
geometric mean (90%CI) Cmax and AUC0- of
amenamevir were about 66(59, 74)% and 82(73,
91)%, respectively, of those after amenamevir alone.
After 1200 mg of amenamevir with cyclosporine,
geometric mean Cmax and AUC0- were about
69(63, 74)% and 79(73, 85)%, respectively, of those
after amenamevir alone. To assess the effect of cy-
closporine on amenamevir, an equivalence analysis
was done. Because the dose by treatment interac-
tion was not significant at the 20% level, it was not
included in the model. The geometric mean ratio
amenamevir with cyclosporine:amenamevir for Cmax
of amenamevir was 67%, ie, below the prespeci-
fied interval 80% to 125%, and the corresponding
figure for AUC0- was 80%, ie, just within the pre-
specified interval 80% to 125%. For both Cmax and
AUC0- the 90%CIs excluded unity. Thus, the dif-
ference between the doses of amenamevir with and
without cyclosporine with respect to pharmacokinetic
parameters was modest in the case of Cmax and minor
in the case of AUC0-, even though the differences
achieved a conventional level of statistical significance.
To assess the effect of cyclosporine on the phar-
macokinetics of the metabolite AS1955888-00, a fur-
ther equivalence analysis was done. Because the dose
by treatment interaction was not significant at the 20%
level, it was not included in the model; the resulting
estimates presented in Table 4 are for both 400-mg
and 1200-mg amenamevir. After amenamevir with cy-
closporine, Cmax and AUC0- of AS1955888-00 were
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Figure 3. Mean midazolam and 1-hydroxymidazolam plasma concentration-time plots (linear and semilog) with and without
amenamevir (n = 18).
about 78% and 92%, respectively, of those after ame-
namevir alone. The 90%CI of the log ratio amenamevir
alone vs amenamevir with cyclosporine, did not fall
within the prespecified interval 80% to 125% for Cmax,
but did for AUC0-. Therefore, a significant drug-
drug effect on plasma concentrations of AS1955888-00
could not be ruled out, as both ratios fell outside the
prespecified interval. However, given that the AUC0-
ratio was close to 100%, any interaction is likely to be
small and of no consequence.
Cyclosporine plasma concentrations were not af-
fected by coadministration with amenamevir (see
Table 5).
The most frequently reported treatment-emergent
adverse events were headache (12.5% in treatment
sessions 1 and 2) and oropharyngeal pain (8.3% in treat-
ment session 1, 16.7% in treatment session 2).
Ritonavir Study
Plasma concentrations and AUC0- of amenamevir
were significantly increased after coadministration with
600 mg of ritonavir compared with administration of
amenamevir alone (see Figure 5 and Table 6).
After amenamevir 400 mg with ritonavir, geomet-
ric mean Cmax and AUC0- of amenamevir were, re-
spectively, about 1.4 and 2.6 times higher than after
amenamevir 400 mg alone. After amenamevir 1200
mg with ritonavir, geometric mean Cmax and AUC0-
of amenamevir were, respectively, about 1.6 and 3.3
times higher than after amenamevir 1200 mg alone
(see Table 7). After 400 mg and 1200 mg of ame-
namevir, the 90%CI of the log ratio amenamevir with
ritonavir:amenamevir did not fall within the range 80%
to 125% for either Cmax or AUC0-, and therefore failed
to exclude a significant drug-drug effect of ritonavir on
those parameters.
Ritonavir increased the geometric mean elimina-
tion half-life of amenamevir from about 7 hours to
about 12 to 13 hours, irrespective of the dose of amen-
amevir.
After dosing of amenamevir with ritonavir, plasma
concentrations of AS1955888-00 were much lower
than after amenamevir monotherapy. Geometric mean
Cmax and AUC0- after amenamevir and ritonavir
coadministration were about 11% and 28%, respec-
tively, of those after 400-mg amenamevir monotherapy,
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Table 2. Summary of Midazolam Pharmacokinetic Parameters (n = 18)
Day 1
Midazolam
7.5 mg Alone
(Control)
Day 12
Midazolam
7.5 mg With
Amenamevir
400 mg
Day 19
Midazolam
7.5 mg Alone
Day 26
Midazolam
7.5 mg Alone
Cmax (ng/mL) Arithmetic mean 35.2 24.5 39.7 39.5
SD 8.1 7.7 8.3 15.5
Geometric mean 34.5 23.4 38.8 36.8
%CVb 21.2 32.5 23.1 41.4
LS mean 34 23 39 37
LS mean ratio vs control
(90%CI) (%)
N/A 68 (59, 78) 113 (96,
132)a
107 (91,
125)a
AUC0–tn (ng  h/mL) Arithmetic mean 115.3 59 127.3 126.2
SD 35.4 17.9 39.5 45.8
Geometric mean 111 56.7 121.9 118.9
%CVb 28 28.8 30.7 36.2
AUC0– (ng  h/mL) Arithmetic mean 117.5 60.3 130.3 130
SD 36.2 18.6 42.6 49.2
Geometric
mean 113.1 58 124.4 122.1
%CVb 28.1 29.2 31.7 37.3
LS mean 113 58 124 122
LS mean ratio vs control
(90%CI) (%)
N/A 51 (47, 56) 110 108
Tmax (h) Median 0.5 0.5 0.5 0.5
Range 0.50-1.52 0.25-1.50 0.50-1.50 0.28-2.00
t1/2 (h) Arithmetic mean 4.5 3.7 4.6 4.6
SD 1.5 1.8 1.8 2
Geometric
mean 4.2 3.3 4.3 4.1
%CVb 37 52.7 43.7 52.3
CL/F (L/h) Arithmetic mean 68.5 134.3 63 65.2
SD 16.9 36.4 18.9 22.3
AUC 0–, area under concentration-time curve extrapolated to infinite time;AUC 0–tn, area under concentration–time curve up to last nonzero value;
CI, confidence interval; CL/F, apparent total body clearance from plasma; Cmax, peak concentration; %CVb, between-subject coefficient of variance; LS,
least squares; SD, standard deviation; t1/2, half-life; Tmax, time of peak concentration.
a 95%CI.
and about 13% and 26%, respectively, of those after
1200-mg amenamevir monotherapy (see Table 8).
Plasma concentrations and AUC0-tn of ritonavir
were similar when ritonavir was given with either
400 mg or 1200 mg of amenamevir (see Figure 6 and
Table 9).
The most frequently reported treatment-emergent
adverse event was headache (16.7% with 400-mg ame-
namevir, 29.2% with 1200-mg amenamevir).
Discussion
Midazolam
Treatment with amenamevir 400 mg once daily for
10 days reduced Cmax of midazolam by about 32%,
and average concentrations (AUC) by about 51%.
Mean elimination half-life was also reduced from
4.2 to 3.3 hours. The reduction in Cmax suggests that
amenamevir increased first-pass intestinal and hepatic
extraction of midazolam to a modest degree. The effect
on AUC was greater, probably because amenamevir
treatment increased the clearance and reduced the half-
life of midazolam, thereby reducing plasma concen-
trations of midazolam beyond the 32% reduction that
would be predicted from the effect on Cmax alone. The
effect of amenamevir was minor compared with that of
a powerful enzyme inducer such as rifampicin: A study
of similar design to ours, but using rifampicin as an
inducer instead of amenamevir, showed that rifampicin
reduced midazolam Cmax 27-fold and AUC 64-fold,
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Figure 4. Mean amenamevir plasma concentration-time plots (linear and semilog) with and without cyclosporine (n = 24).
and shortened mean elimination half-life from 3.2 to
1.8 hours.13
Our results show that 10 days’ treatment with ame-
namevir 400 mg once daily induced the activity of
CYP3A in the intestine and liver, but the effect was only
moderate and was no longer evident at 7 and 14 days
after the end of amenamevir treatment. The reversal of
amenamevir’s enzyme-inducing effect was much more
rapid than has been reported after rifampicin, whose
effect on the pharmacokinetics of midazolam may take
3 weeks to reverse,13 presumably because the inducing
effect of rifampicin is somuch greater than that of ame-
namevir.
Plasma concentrations of 1-hydroxymidazolam, the
main metabolite of midazolam, were not affected
by coadministration of amenamevir with midazolam.
Concentrations of 1-hydroxymidazolam might be ex-
pected to increase because of induction of the
metabolism of midazolam by amenamevir, but that ex-
pectation is incorrect: 1-hydroxymidazolam is cleared
by glucuronidation, and hepatic enzyme induction
increases the activity of glucuronyltransferases. It
has been shown convincingly that hepatic enzyme
induction by rifampicin leads to a reduction in
plasma concentrations of 1-hydroxymidazolam that is
greater than the corresponding reduction in parent
midazolam.13
Cyclosporine
After single doses of amenamevir 400 mg or 1200 mg
given on day 5 of 7 days’ treatment with cy-
closporine 100mg twice daily, plasma concentrations of
amenamevir were lower than when the same doses of
amenamevir had been given before the start of cy-
closporine treatment. The interval between doses of
amenamevir was 6 days. Results were similar after both
the 400-mg and 1200-mg dose levels of amenamevir:
Taking the average result for the 2 dose levels, Cmax
and AUC of amenamevir given with cyclosporine were
about 67% and 80%, respectively, of values obtained
after the dose of amenamevir given 6 days previously.
We were surprised by that result: cyclosporine is an
inhibitor of CYP3A7 and therefore might have been
expected to reduce first-pass metabolism and clearance
of amenamevir, leading to increased plasma concentra-
tions. However, amenamevir is not only a substrate of
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Table 3. Summary of Amenamevir Pharmacokinetic Parameters From Cyclosporine Study (n = 24)
Amenamevir 400 mg Amenamevir 1200 mg
Amenamevir
Alone
(Control)
Amenamevir
With Cy-
closporine
Amenamevir
Alone
(Control)
Amenamevir
With
Cyclosporine
Cmax (ng/mL) Arithmetic mean 1875.3 1260.6 3681.8 2563.0
SD 475.6 418.3 886.5 782.0
Geometric mean 1818.0 1202.3 3573.1 2452.1
%CVb 26.1 31.5 26.1 31.4
LS mean 2568 1730 2568 1730
LS mean ratio vs
control (90%CI) (%)
N/A 67 (63, 72) N/A 67 (63, 72)
AUC0-tn (ng  h/mL) Arithmetic mean 23 670.0 19 755.6 48 655.9 38 867.0
SD 6221.1 7094.7 12 353.3 9143.8
Geometric mean 22 903.1 18 784.4 47 282.0 37 734.2
%CVb 26.7 31.8 24.6 26.1
AUC0- (ng  h/mL) Arithmetic mean 24 111.7 19 973.7 49 496.4 39 066.6
SD 6430.1 7116.8 12876.8 9176.1
Geometric mean 23 307.4 19 013.5 48 051.2 37 940.8
%CVb 27.1 31.4 25.0 25.9
LS mean 33 764 27 098 33 764 27 098
LS mean ratio vs
control (90%CI) (%)
N/A 80 (75, 86) N/A 80 (75, 86)
Tmax (h) Median 3.00 4.00 3.00 4.00
Range 0.50-4.02 1.00-8.00 2.00-4.00 2.00-8.00
t1/2 (h) Arithmetic mean 7.8 8.7 7.5 8.4
SD 0.9 1.4 1.0 1.1
Geometric mean 7.8 8.6 7.5 8.3
%CVb 12.1 16.4 13.2 14.1
CL/F (L/h) Arithmetic mean 17.7 21.9 25.7 32.7
SD 4.6 5.9 6.3 9.3
AUC 0–, area under concentration–time curve extrapolated to infinite time;AUC 0–tn, area under concentration-time curve up to last nonzero value;
CI, confidence interval; CL/F, apparent total body clearance from plasma; Cmax, peak concentration; %CVb, between-subject coefficient of variance; LS,
least squares; SD, standard deviation; t1/2, half-life; Tmax, time of peak concentration.
Table 4. Least Squares Means and Ratios of AUC0- and Cmax for AS1955888-00 Before Cyclosporine Treatment and on the Fifth
Day of Dosing With Cyclosporine 100 mg Twice Daily (n = 24)
LS Means
Amenamevir With Cyclosporine vs
Amenamevir Alone
Amenamevir Alone
Amenamevir With
Cyclosporine Ratio (%) 90%CI
Cmax (ng/mL) 256 200 78 72, 84
AUC0- (ng  h/mL) 3987 3672 92 86, 99
AUC0-, area under concentration-time curve extrapolated to infinite time; CI, confidence interval; Cmax, peak concentration; LS, least squares.
CYP3A but also an inducer; see the results of our study
of the effect of amenamevir on the pharmacokinetics
of midazolam above. Although it is theoretically possi-
ble that our paradoxical result could have been due to
amenamevir inducing its own metabolism, that seems
very unlikely because the results of our midazolam
study show that any induction of CYP3A by repeated
doses of amenamevir was fully reversed by 7 days after
the last dose (see Table 2).
Cyclosporine is an inhibitor of P-gp5: Because
amenamevir is a P-gp substrate, we would again
expect inhibition of P-gp by cyclosporine to increase
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Table 5. Least Squares Means and Ratios of AUC0-t and Cmax for Cyclosporine Before (Day 6) and After a Single Dose of Amenamevir
(n = 24)
LS Means
Cyclosporine
(Day 6)
Amenamevir
With
Cyclosporine
(Day 7)
Ratio (%)
Day 7/Day 6 90%CI
Cmax (μg/mL) 480 462 96 92, 101
AUC0-τ (ng  h/mL) 1931 1960 102 99, 105
AUC0–τ , area under concentration-time curve over the dosing interval; CI, confidence interval; Cmax, peak concentration; LS, least squares.
Figure 5. Mean amenamevir plasma concentration-time plots (linear and semilog) with and without ritonavir (n = 24).
amenamevir plasma concentrations rather than de-
crease them, as occurred in this study. Our findings
with respect to unchanged amenamevir are con-
sistent with the report of Hesselink et al14 on the
effects of cyclosporine on the pharmacokinetics of
mycophenolate mofetil: Coadministration of my-
cophenolate mofetil with cyclosporine to solid-organ
transplant recipients reduced mycophenolic acid con-
centrations and increased exposure to its metabolite,
mycophenolic acid–glucuronide (MPAG), possibly by
interfering with the biliary excretion of MPAG.14 The
authors of that report suggested a role for multidrug
resistance-associated protein-2 in that interaction, as
it was not observed in multidrug resistance-associated
protein-2–deficient rats.
In contrast with the results of Hesselink et al14
with respect to the MPAG metabolite of mycopheno-
late mofetil, we found that plasma concentrations of
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Table 6. Summary of Amenamevir Pharmacokinetic Parameters From Ritonavir Study (n = 24)
Amenamevir 400 mg Amenamevir 1200 mg
Amenamevir
Alone
(N = 24)
Amenamevir With
Ritonavir 600 mg
(N = 24)
Amenamevir
Alone
(N = 24)
Amenamevir With
Ritonavir 600 mg
(N = 24)
Cmax (ng/mL) Arithmetic mean 1896.7 2568.3 3948.2 6457.4
SD 418.5 459.8 1096.5 1855.0
Geometric mean 1845.7 2518.7 3804.0 6211.6
%CVb 25.4 21.9 28.8 29.2
AUC0-tn (ng  h/mL) Arithmetic mean 24 113.8 59 926.3 50 141.0 161 853.7
SD 7029.9 12 482.1 13 944.6 38 163.6
Geometric mean 22 987.3 58 616.1 48 245.8 157 352.7
% CVb 34.2 22.2 29.3 25.1
AUC0- (ng  h/mL) Arithmetic mean 24 296.0 61 678.1 50 440.3 166 855.3
SD 7072.3 13 384.7 14 021.9 39 814.1
Geometric mean 23 162.4 60 225.3 48 532.3 162 131.6
%CVb 34.2 23.0 29.3 25.3
Tmax (h) Median 3 4 3 4
Range 1.00-4.00 1.00-10.00 1.00-4 2.00-12.00
t1/2 (h) Arithmetic mean 7.5 12.7 7.3 12.7
SD 1.2 2.2 1.4 2.5
Geometric mean 7.4 12.6 7.2 12.5
%CVb 14.9 15.9 17.5 19.6
CL/F (L/h) Arithmetic mean 18.3 6.8 25.7 7.6
SD 7.3 1.7 7.6 2.0
AUC0–, area under concentration-time curve extrapolated to infinite time; AUC0-tn, area under concentration-time curve up to last nonzero value;
CL/F, apparent total body clearance from plasma;Cmax, peak concentration; %CVb: between-subject coefficient of variance; SD, standard deviation; t1/2,
half-life; tmax, time of peak concentration.
Table 7. Least Squares Means and Ratios of AUC0- and Cmax for 400- and 1200-mg Amenamevir With and Without Coadministra-
tion of 600-mg Ritonavir (n = 24)
LS Means
Amenamevir With Ritonavir vs
Amenamevir Alone
Amenamevir
Dose
Amenamevir
Alone
Amenamevir
With
Ritonavir Ratio (%) 90%CI
400 mg Cmax (ng/mL) 1846 2519 136 124, 151
AUC0- (ng  h/mL) 23 162 60 225 260 234, 289
1200 mg Cmax (ng/mL) 3804 6212 163 146, 182
AUC0- (ng  h/mL) 48 532 162 132 334 305, 366
AUC0–, area under concentration-time curve extrapolated to infinite time; CI: confidence interval; Cmax, peak concentration; LS, least squares.
amenamevir’s main metabolite, AS1955888-00, were
lower after the second dose of amenamevir (coadminis-
teredwith cyclosporine) than after the first dose of ame-
namevir, which was given alone. Although plasma con-
centrations of AS1955888-00 might have been expected
to be higher, because of increased hepatic metabolism
of amenamevir after the second dose, experience with
the metabolites of midazolam13 (see above) shows that
the reverse may be the case in practice.
An important limitation of the design of our study
is that it did not include a control arm in which sin-
gle doses of amenamevir were given on days 1 and 7 in
the absence of any treatment with cyclosporine. As a
result of that limitation, we cannot determine whether
cyclosporine treatment had any effect on the plasma
concentrations of amenamevir. A further study would
be needed to elucidate the matter fully. For the present,
however, we can safely conclude that cyclosporine
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Table 8. Least Squares Means and Ratios of AUC0- and Cmax for AS1955888-00 With and Without Coadministration of 600-mg
Ritonavir (n = 24)
LS Mean
Amenamevir With Ritonavir vs
Amenamevir Alone
Amenamevir
Dose
AS1955888-00
Parameter
Amenamevir
Alone
Amenamevir
With
Ritonavir Ratio (%) 90%CI
400 mg Cmax (ng/mL) 190 22 11 9, 14
AUC0- (ng  h/mL) 2636 739 28 24, 33
1200 mg Cmax (ng/mL) 421 56 13 10, 17
AUC0- (ng  h/mL) 6023 1587 26 22, 32
AUC0–, area under concentration–time curve extrapolated to infinite time; CI: confidence interval; Cmax, peak concentration; LS, least squares.
Figure 6. Mean (SD) ritonavir plasma concentration versus time (linear and semilog); (n = 24*) *at the 24-hour time point, n = 4
for 400 mg; and n = 2 for 1200-mg amenamevir.
treatment does not increase plasma concentrations of
amenamevir.
Two single doses of amenamevir 400 mg and
1200 mg, given 7 days apart, had no effect on the phar-
macokinetics of cyclosporine. Because amenamevir is
both a substrate and an inducer of CYP3A, it has the
potential to produce opposing effects on cyclosporine
concentrations that might cancel each other out.
Ritonavir
A single 600-mg dose of ritonavir substantially in-
creased plasma concentrations of amenamevir after
coadministration with either 400-mg or 1200-mg
doses. The increase in Cmax was about 1.5-fold, which
is consistent with a modest decrease in first-pass
extraction of amenamevir. In contrast, AUC increased
>3-fold, reflecting the dual contributions of decreased
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Table 9. Summary of Ritonavir Pharmacokinetic Parameters (n = 24)
Amenamevir 400 mg and
Ritonavir 600 mg (N = 24)
Amenamevir 1200 mg and
Ritonavir 600 mg (N = 24)
Cmax (μg/mL) Arithmetic mean 13.6 12.9
SD 3.7 3.7
Geometric mean 13.2 12.4
%CVb 26.6 29.8
AUC0-tn (μg  h/mL) n 24 24
Arithmetic mean 87.3 78.1
SD 31.4 29.9
Geometric mean 82.5 72.6
%CVb 34.9 41.3
AUC0- (μg  h /mL) n 14 13
Arithmetic mean 98.1 77.7
SD 37.5 32.2
Geometric mean 92.1 71.8
%CVb 37.7 44.0
Tmax (h) n 24 24
Median 4.0 4.0
Range 3.00-6.00 2.00-4.22
t1/2 (h) n 24 24
Arithmetic mean 5.0 4.5
SD 2.9 2.1
Geometric mean 4.5 4.1
%CVb 47.7 47.9
AUC0–, area under concentration-time curve extrapolated to infinite time; AUC0-tn, area under concentration-time curve up to last nonzero value;
Cmax, peak concentration; %CVb, between-subject coefficient of variance; t1/2, half-life; tmax, time of peak concentration.
first-pass extraction and reduced clearance. These
findings are similar to those of Kusawake et al,15
who coadministered amenamevir with ketoconazole,
another CYP3A inhibitor. In that study, the geometric
mean ratio of amenamevir plus ketoconazole vs ame-
namevir alone for Cmax and AUCinf was 1.30 (90%CI,
1.17-1.45) and 2.58 (90%CI, 2.32-2.87), respectively.15
Elimination half-life of amenamevir after both 400-mg
and 1200-mg doses was increased from about 7 hours
to about 12 to 13 hours by a single dose of ritonavir
600 mg. Plasma concentrations of the metabolite
AS1955888-00 were much lower when amenamevir
was given with ritonavir compared with amenamevir
alone, reflecting decreased hepatic metabolism of
amenamevir.
Amenamevir is a substrate of P-gp in vitro, and ri-
tonavir inhibits P-gp as well as CYP3A.16 Inhibition of
P-gp by ritonavir in the intestinal epithelium could have
contributed to the observed increases in Cmax and AUC
of amenamevir, and could also have contributed to the
prolongation of elimination half-life by reducing trans-
port into bile.
Single doses of amenamevir 400mg and 1200mg did
not affect the pharmacokinetics of ritonavir.
Conclusions
As predicted from in vitro metabolic studies of ame-
namevir, our 3 clinical studies confirm the existence
of interactions between amenamevir and midazolam (a
probe substrate for CYP3A), cyclosporine (a substrate
and inhibitor of CYP3A), and ritonavir (an inhibitor
of CYP3A). In our healthy volunteers, amenamevir in-
duced the metabolism and enhanced the clearance of
midazolam. Cyclosporine decreased Cmax and AUC of
amenamevir; further studies would be needed to iden-
tify the mechanism of that interaction. Ritonavir, even
when given as a single dose, substantially inhibited the
clearance of amenamevir.
The CYP3A-inducing effect of amenamevir caused
a 52% reduction in plasma concentrations of the probe
drug midazolam, and might be expected to have a sim-
ilar effect on the plasma concentrations of other drugs
that are substrates of CYP3A. Halving plasma con-
centrations might have important consequences in the
case of drugs with a narrow therapeutic window but
would probably be of no consequence for others. The
prescriber would have to make an informed decision
in each case. However, if a prescriber were to double
the dose of a drug to maintain plasma concentrations
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during amenamevir treatment, it would be important
to reduce the dose of that drug within a few days of the
end of amenamevir treatment, as the enzyme-inducing
effect clearly wanes rapidly.
Although our study has not fully defined the poten-
tial interactions between cyclosporine and amenamevir,
the results are reassuring in that they show that cy-
closporine does not increase plasma concentrations of
amenamevir, and any reduction by cyclosporine is un-
likely to be greater than that attributable to autoin-
duction of metabolism of amenamevir. Single doses of
amenamevir up to 1200 mg have no effect on the phar-
macokinetics of cyclosporine.
As demonstrated by the ritonavir study, concentra-
tions of amenamevir are likely to be substantially in-
creased by coadministration of inhibitors of CYP3A,
such as erythromycin, itraconazole, or ritonavir.
Amenamevir clearly has the potential to be involved
in CYP3A-mediated pharmacokinetic interactions in
clinical practice. Prescribers should therefore consider
the need for dose adjustment when amenamevir is
coadministered with other CYP3A substrates, in-
hibitors, or inducers.
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